Results 121 to 130 of about 6,976 (185)

HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers. [PDF]

Cancers (Basel)
Bagegni NA, Giridhar KV, Stewart D.
europepmc   +1 more source

Supplementary Figure 1 from Co-clinical study of [fam-] trastuzumab deruxtecan (DS8201a) in patient-derived xenograft models of uterine carcinosarcoma and its association with clinical efficacy

Shigehiro Yagishita, Tadaaki Nishikawa, Hiroshi Yoshida, Daisuke Shintani, Sho Sato, Maiko Miwa, Mikiko Suzuki, Masanori Yasuda, Yusuke Ogitani, Takahiro Jikoh, Kan Yonemori, Kosei Hasegawa, Akinobu Hamada   +12 more
openalex   +1 more source

Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer. [PDF]

ESMO Open
Antonarelli G, Milano M, Andreon C, Gandini S, Pellizzari G, Trapani D, Dellapasqua S, Marra A, Zagami P, Valenza C, Colleoni M, Munzone E, Curigliano G.   +12 more
europepmc   +1 more source

Supplementary Data from Perivascular Niche–Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment

Qing Wei, Teng Yang, Ziwen Zhang, Fei Wang, Yuxuan Yang, Jiayu Zhu, Xiu Zhu, Y. Li, Yun Xing, Ye Lu, Xuefei Tian, Mengyang Fan, Yuchao Zhang, Xu Xue, Meng Li, Chuanfei Yu, Lan Wang, Takaya Shimura, Jianmin Fang, Zhiwei Cao, Jieer Ying, Peng Guo, Xiangdong Cheng   +22 more
openalex   +1 more source

261TiP Randomized, open-label, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with rilvegostomig vs standard of care (SOC) in first-line, human epidermal growth factor receptor 2 (HER2)-expressing, locally advanced or metastatic (LA/m) biliary tract cancer (BTC): DESTINY-BTC01 [PDF]

Masafumi Ikeda, Ming Kuang, D-Y. Oh, G. Cohen, Saeed Raoufmoghaddam, Matthew Winter, Milind Javle   +6 more
openalex   +1 more source

Successful Rechallenge of Trastuzumab Deruxtecan Following Early Detection of ILD in a Patient with Non-small Cell Lung Carcinoma Harboring HER2 Exon 20 Insertion

Yuichiro Yasuda, Yoshihiro Hattori, Miyako Satouchi   +2 more
openalex   +2 more sources

Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports. [PDF]

Front Oncol
Ballatore Z, Vanacker H, Chiari R, Bachelot T.   +3 more
europepmc   +1 more source

Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study. [PDF]

Future Oncol
Van Cutsem E.
europepmc   +1 more source

Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study. [PDF]

Therap Adv Gastroenterol
Narita Y, Kumanishi R, Takahashi K, Masuishi T, Taniguchi H, Kadowaki S, Honda K, Ando M, Fukui T, Tajika M, Muro K.   +10 more
europepmc   +1 more source

Case Report: Possible association between dermatomyositis and Trastuzumab Deruxtecan therapy of triple-negative breast cancer patient. [PDF]

Front Immunol
Han H, Semenov M, Li C, Zhang Y, Lin T, Zheng P, Cai J.   +6 more
europepmc   +1 more source